Newcomb Polly A, Adams Scott V, Mayer Sophie, Passarelli Michael N, Tinker Lesley, Lane Dorothy, Chlebowski Rowan T, Crandall Carolyn J
Department of Epidemiology, University of Washington, Seattle, WA.
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
JNCI Cancer Spectr. 2018 Jan;2(1):pky001. doi: 10.1093/jncics/pky001. Epub 2018 Mar 21.
Postmenopausal bone fracture's have been proposed as a marker of lifetime estrogen exposure and have been associated with decreased risk of breast and endometrial cancer. It is plausible that prediagnostic fractures may be related to survival of estrogen-sensitive cancers.
We evaluated a cohort of breast (n = 6411), endometrial (n = 1127), and ovarian (n = 658) cancer cases diagnosed between 1992 and 2010 while participating in the Women's Health Initiative. Postmenopausal fracture history was assessed from baseline reports of fractures after age 55 years and incident fractures that occurred at least one year prior to cancer diagnosis during study follow-up. Using Cox regression, we compared women with and without a history of fractures with respect to overall and cancer-specific survival. Estimates were adjusted for participant factors, including hormone therapy use; hormone receptor status was not included in our analysis.
Among women with breast cancer, a history of prediagnostic fractures at any site was associated with poorer overall survival (hazard ratio [HR] = 1.22, 95% confidence interval [CI] = 1.05 to 1.43). A history of hip, forearm, or spine fractures, or hip fracture alone, was associated with increased risk of mortality (HR = 1.26, 95% CI = 1.01 to 1.58, and HR = 2.05, 95% CI = 1.27 to 3.32, respectively). Fracture history was associated neither with cancer-specific survival among breast cancer survivors, nor with overall or disease-specific mortality among endometrial and ovarian cancer survivors.
Postmenopausal breast cancer patients with a history of fractures, especially of the hip, are more likely to die of any cause than breast cancer survivors without a fracture history. Identifying and intervening in fracture risk factors should be standard of care for all women diagnosed with breast cancer.
绝经后骨折被认为是终生雌激素暴露的一个标志,并且与乳腺癌和子宫内膜癌风险降低相关。诊断前骨折可能与雌激素敏感性癌症的生存率有关,这是有道理的。
我们评估了1992年至2010年间参与妇女健康倡议的一组乳腺癌(n = 6411)、子宫内膜癌(n = 1127)和卵巢癌(n = 658)病例。绝经后骨折史通过55岁以后骨折的基线报告以及研究随访期间癌症诊断前至少一年发生的新发骨折来评估。使用Cox回归,我们比较了有和没有骨折史的女性在总生存率和癌症特异性生存率方面的情况。估计值针对参与者因素进行了调整,包括激素治疗的使用;我们的分析未包括激素受体状态。
在乳腺癌女性中,任何部位诊断前骨折史与较差的总生存率相关(风险比[HR] = 1.22,95%置信区间[CI] = 1.05至1.43)。髋部、前臂或脊柱骨折史,或仅髋部骨折史,与死亡风险增加相关(HR分别为1.26,95%CI = 1.01至1.58,以及HR = 2.05,95%CI = 1.27至3.32)。骨折史与乳腺癌幸存者的癌症特异性生存率无关,也与子宫内膜癌和卵巢癌幸存者的总死亡率或疾病特异性死亡率无关。
有骨折史,尤其是髋部骨折史的绝经后乳腺癌患者比没有骨折史的乳腺癌幸存者更有可能死于任何原因。识别和干预骨折风险因素应该是所有被诊断为乳腺癌的女性的标准治疗措施。